Regardless of the sequential decrease in Current Liabilities, during the first quarter 2023, Quick Ratio deteriorated to 0.12 a new company low.

Within Biotechnology & Pharmaceuticals industry 177 other companies have achieved higher Quick Ratio than Aceragen Inc in first quarter 2023. While Quick Ratio total ranking in the first quarter 2023 has deteriorated compared to the prior quarter from 3657 to 4953.

Explain Quick Ratio?
How much Cash & cash equivalents ACGN�s has?
What are ACGN�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ACGN Quick Ratio	(Mar 31 2023) Q1	(Dec 31 2022) Q4	(Sep 30 2022) Q3	(Jun 30 2022) Q2	(Mar 31 2022) Q1
Y / Y Current Liabilities Change	370.57 %	340.62 %	245.51 %	-21.45 %	-24.02 %
Y / Y Cash & cash equivalent Change	-92.43 %	-62.99 %	-26.79 %	-39.69 %	-37.15 %
Quick Ratio MRQ	0.12	0.56	1.39	5.17	7.37
ACGN's Total Ranking	# 4953	# 3657	# 2511	# 1280	# 1095
Seq. Current Liabilities Change	-16.62 %	11.4 %	306.06 %	24.76 %	-21.93 %
Seq. Cash & cash equivalent Change	-82.41 %	-55.05 %	9.46 %	-12.55 %	-13.99 %

Quick Ratio first quarter 2023 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 178
Healthcare Sector	# 1140
Overall Market	# 4853

Quick Ratio Statistics
High	Average	Low
18.48	7.16	0.12
(Mar 31 2015)		(Mar 31 2023)

Financial Statements
Aceragen Inc 's Current Liabilities	$ 18 Millions	Visit ACGN's Balance sheet
Aceragen Inc 's Cash & cash equivalent	$ 2 Millions	Visit ACGN's Balance sheet
Source of ACGN's Sales		Visit ACGN's Sales by Geography

Cumulative Aceragen Inc 's Quick Ratio

ACGN's Quick Ratio for the trailling 12 Months

ACGN Quick Ratio	(Mar 31 2023) 12 Months	(Dec 31 2022) 12 Months	(Sep 30 2022) 12 Months	(Jun 30 2022) 12 Months	(Mar 31 2022) 12 Months
Y / Y Current Liabilities TTM Growth	212.31 %	129.27 %	41.9 %	-21.75 %	-21.3 %
Y / Y Cash & cash equivalent TTM Growth	-52.49 %	-40.81 %	-29.88 %	-19.9 %	-3.18 %
Quick Ratio TTM	1.03	1.86	3.43	6.41	6.8
Total Ranking TTM	# 4500	# 4410	# 3924	# 3698	# 3554
Seq. Current Liabilities TTM Growth	28.6 %	50.76 %	72.07 %	-6.38 %	-5.59 %
Seq. Cash & cash equivalent TTM Growth	-28.34 %	-18.34 %	-8.06 %	-11.7 %	-10.73 %

Quick ratio ranking by company, industry and sector >> Back to ACGN Financial Strength Comparisons >> Go to Compare ACGN Quick Ratio to its Competitors

On the trailing twelve months basis Due to decline in Current Liabilities in the Q1 2023 to $17.86 millions, cumulative Quick Ratio decreased to 1.03 below the Aceragen Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 184 other companies have achieved higher Quick Ratio than Aceragen Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2022 from 4410 to 4500.

Explain Quick Ratio?
How much Cash & cash equivalents ACGN�s has?
What are ACGN�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 185
Healthcare Sector	# 1172
Within the Market	# 4500

trailing twelve months Quick Ratio Statistics
High	Average	Low
12.53	7.58	1.03
(Dec. 30, 2015)		(Mar 31 2023)

Companies with similar Quick Ratio in the quarter ending Mar 31 2023, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Mar 31 2023 MRQ Cash & cash equivalent	Mar 31 2023 MRQ Current Liabilities
Novavax inc	0.33	$ 624.950 Millions	$ 1,918.858 Millions
Apeiron Capital Investment Corp	0.31	$ 0.631 Millions	$ 2.005 Millions
Sorrento Therapeutics Inc	0.30	$ 50.317 Millions	$ 165.632 Millions
Xtant Medical Holdings Inc	0.30	$ 5.176 Millions	$ 17.276 Millions
Eloxx Pharmaceuticals Inc	0.26	$ 4.904 Millions	$ 18.793 Millions
Ladrx Corporation	0.26	$ 0.606 Millions	$ 2.348 Millions
Brainstorm Cell Therapeutics inc	0.21	$ 2.227 Millions	$ 10.422 Millions
Galaxy Enterprises Inc	0.21	$ 1,544.000 Millions	$ 7,504.000 Millions
Cyclo Therapeutics Inc	0.20	$ 0.915 Millions	$ 4.483 Millions
Immunitybio inc	0.16	$ 91.268 Millions	$ 564.945 Millions
Aceragen Inc	0.12	$ 2.118 Millions	$ 17.863 Millions
Enzo Biochem Inc	0.10	$ 2.632 Millions	$ 25.289 Millions
Kiromic Biopharma Inc	0.10	$ 2.054 Millions	$ 19.860 Millions
Atlantic Coastal Acquisition Corp Ii	0.10	$ 0.295 Millions	$ 3.083 Millions
Gilead Sciences Inc	0.09	$ 936.000 Millions	$ 10,528.000 Millions
Scilex Holding Company	0.08	$ 5.069 Millions	$ 64.602 Millions
Tevogen Bio Holdings Inc	0.08	$ 0.052 Millions	$ 0.667 Millions
Futuretech Ii Acquisition Corp	0.06	$ 0.150 Millions	$ 2.345 Millions
Nkgen Biotech Inc	0.06	$ 0.207 Millions	$ 3.528 Millions
Phoenix Biotech Acquisition Corp	0.05	$ 0.178 Millions	$ 3.293 Millions
Mosaic Immunoengineering Inc	0.04	$ 0.126 Millions	$ 3.386 Millions
Peak Bio Inc	0.03	$ 0.564 Millions	$ 16.823 Millions
Tradeup Acquisition Corp	0.02	$ 0.029 Millions	$ 1.216 Millions

Date modified: 2026-09-18T13:11:05+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.